548 Odcinki

  1. Forging a Research Agenda for a Rare Disease

    Opublikowany: 25.07.2018
  2. Making the Journey from All-American Athlete to Rare Disease Advocate

    Opublikowany: 18.07.2018
  3. How Destiny Lamonte Learned to Advocate for Herself and Others

    Opublikowany: 11.07.2018
  4. Where the NIH Does Its Banking

    Opublikowany: 5.07.2018
  5. Making Sense of Nonsense Mutations

    Opublikowany: 27.06.2018
  6. Rewriting Faulty RNA

    Opublikowany: 20.06.2018
  7. Experimental Drug for "Elephant Man" Disease May Benefit Certain Cancers Too

    Opublikowany: 13.06.2018
  8. Programming Stem Cells to Protect Neurons in ALS and other Neurodegenerative Conditions

    Opublikowany: 6.06.2018
  9. Why a Topical, Off-the-Shelf, Gene Therapy May Hold Promise for a Rare Skin Condition

    Opublikowany: 30.05.2018
  10. An Ironman Champion with Cystic Fibrosis Discusses her Changing Relationship with Her Disease

    Opublikowany: 23.05.2018
  11. Why an Experimental Fragile X Drug May Treat a Range of Neurodegenerative Diseases

    Opublikowany: 16.05.2018
  12. The Case for a Daily Self-Injection to Treat Hemophilia

    Opublikowany: 9.05.2018
  13. Addressing the Challenges of R&D for Rare Cancer Therapies

    Opublikowany: 2.05.2018
  14. Learning to Communicate and Collaborate as a Patient Advocate

    Opublikowany: 25.04.2018
  15. Seeking Answers for Undiagnosed Patients

    Opublikowany: 18.04.2018
  16. When "Undiagnosed" Is Your Diagnosis

    Opublikowany: 11.04.2018
  17. The Decision to Get Tested for Huntington's Disease and How It Changed Seth Rotberg's Life

    Opublikowany: 4.04.2018
  18. Nonprofit Sees Need in Developing Gene Therapies for Inherited Eye Disesases

    Opublikowany: 29.03.2018
  19. Casting a Wider Net for Genetic Diseases

    Opublikowany: 21.03.2018
  20. Corbus Seeks to Quiet the Immune System in Chronic Conditions

    Opublikowany: 14.03.2018

19 / 28

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Visit the podcast's native language site